Relmada Therapeutics ( (RLMD) ) has shared an update.

Relmada Therapeutics Inc (RLMD) stock saw a decline, ending the day at $0.45 which represents a decrease of $-0.07 or -13.46% from the prior close of $0.52. The stock opened at $0.52 and touched a low ...

Mizuho has recently reduced Relmada Therapeutics Inc (RLMD) stock to Neutral rating, as announced on December 5, 2024, according to Finviz. Earlier, on September 17, 2024, Jefferies had raised the ...

Inverted Hammer 15 68 Dec 23, 2024 14:30 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Relmada Therapeutics (NASDAQ:RLMD) has announced its financial results for the fourth quarter and full year of 2023, focusing on the advancement of its Phase 3 program for ...

On Tuesday, Jefferies, a global investment banking firm, upgraded Relmada Therapeutics Inc (NASDAQ:RLMD) stock from Hold to Buy, significantly raising the price target to $13.00 ...

STAMFORD, Conn. and HOUSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) and Tvardi Therapeutics, Inc. (“Tvardi”), a privately held ...

PURCHASE, N.Y., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...

Investing.com – U.S. equities were higher at the close on Monday, as gains in the Oil & Gas, Financials and Technology sectors propelled shares higher. At the close in NYSE, the... Investing.com – U.S ...